To view a copy of this licence, visit About this article Cite this article Al-Omari, A., Trk, I., Zsid, B.Z
PMID 12191709
nejm.org Eli Lilly
The challenge is in selecting the questions, the right tools (artificial intelligence (AI) based such as machine learning (ML), deep learning (DL), or other, advanced, or classical methods) to target them, and the protocols (Zeng et al., 2022)
Unexpected Symptoms Reported by GLP-1 Users What stood out to researchers were symptoms that may not be fully represented in current drug labeling or standard adverse event reporting systems
Coenzyme cellular energy IV/SubQ 100500 mg Mitochondrial-derived peptide preclinical 35x weekly 510 mg Mitochondrial-derived peptide preclinical no approved human dose Mitochondria-targeting peptide FDA-approved only for Barth syndrome daily 440 mg AEDG tetrapeptide bioregulator research-use 1020 day cycles Senolytic peptide preclinical only no validated human dose Endogenous antioxidant oral/liposomal/IV context 2501,000 mg oral study range MC receptor agonist preclinical loading + maintenance 250500 mcg Also listed under Repair skin remodeling topical/SubQ 12 mg Sexual Health & Hormonal Peptides studied for sexual response and hormonal pathways
